Toripalimab,Nivolumab,Ipilimumab,Cisplatin,Vinorelbine,Gemcitabine,Docetaxel,Pemetrexed,Carboplatin,Paclitaxel,Pembrolizumab,Durvalumab,Atezolizumab
Coherus,Junshi Biosciences,merck,bms,Astrazeneca,Roche
['lung']
more options now for ios in early stage lung cancer- pre op, post op or both? sounds like we do need further research on how we can select the pts that need further adjuvant io as what the discussant suggested via path response as an attempt to prevent overtreatment.#asco23 
Medical Oncologist, Tan Tock Seng Hospital Singapore with subspecialty interests in thoracic and GU oncology